Success Metrics

Clinical Success Rate
100.0%

Based on 9 completed trials

Completion Rate
100%(9/9)
Active Trials
0(0%)
Results Posted
78%(7 trials)

Phase Distribution

Ph phase_3
1
11%
Ph phase_4
2
22%
Ph phase_2
2
22%
Ph not_applicable
3
33%

Phase Distribution

0

Early Stage

2

Mid Stage

3

Late Stage

Phase Distribution8 total trials
Phase 2Efficacy & side effects
2(25.0%)
Phase 3Large-scale testing
1(12.5%)
Phase 4Post-market surveillance
2(25.0%)
N/ANon-phased studies
3(37.5%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

9 of 9 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

9

all time

Status Distribution
Completed(9)

Detailed Status

Completed9

Development Timeline

Analytics

Development Status

Total Trials
9
Active
0
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 22 (25.0%)
Phase 31 (12.5%)
Phase 42 (25.0%)
N/A3 (37.5%)

Trials by Status

completed9100%

Recent Activity

Clinical Trials (9)

Drug Details

Intervention Type
DRUG
Total Trials
9